Interneurons and beta-amyloid in the olfactory bulb, anterior olfactory nucleus and olfactory tubercle in appxps1 transgenic mice model of Alzheimer's disease

Anatomical Record

Volumn 296, Issue 9, 2013, Pages 1413-1423

  Saiz Sanchez, Daniel ^a   De La Rosa Prieto, Carlos ^a   Ubeda Bañon, Isabel ^a   Martinez Marcos, Alino ^a  

^a UNIVERSITY OF CASTILLA LA MANCHA   (Spain)

Author keywords

Alzheimer's disease; Amyloid beta; Calretinin; Olfactory bulb; Olfactory deficit; Parvalbumin; Somatostatin; Transgenic mice

Indexed keywords

AMYLOID BETA PROTEIN; CALRETININ; PARVALBUMIN; SOMATOSTATIN;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DISEASE COURSE; FEMALE; INTERNEURON; MOUSE; NONHUMAN; OLFACTORY BULB; OLFACTORY NUCLEUS; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS;

ANIMALIA; MUS MUSCULUS;

ALZHEIMER'S DISEASE; AMYLOID BETA; CALRETININ; OLFACTORY BULB; OLFACTORY DEFICIT; PARVALBUMIN; SOMATOSTATIN; TRANSGENIC MICE;

AGE FACTORS; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; CALBINDIN 2; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; FEMALE; HOMOZYGOTE; HUMANS; INTERNEURONS; MICE; MICE, TRANSGENIC; OLFACTORY BULB; OLFACTORY PATHWAYS; PARVALBUMINS; PRESENILIN-1; SMELL; SOMATOSTATIN; TIME FACTORS;

EID: 84882570351     PISSN: 19328486     EISSN: 19328494     Source Type: Journal    
DOI: 10.1002/ar.22750     Document Type: Article

References (76)

1. Atanasova B, Graux J, El Hage W, Hommet C, Camus V, Belzung C. 2008. Olfaction: a potential cognitive marker of psychiatric disorders. Neurosci Biobehav Rev 32:1315-1325.
2. Attems J, Jellinger KA. 2006. Olfactory tau pathology in Alzheimer disease and mild cognitive impairment. Clin Neuropathol 25:265-271.
3. Attems J, Lintner F, Jellinger KA. 2005. Olfactory involvement in aging and Alzheimer's disease: an autopsy study. J Alzheimers Dis 7:149-157; discussion 173-180.
4. Baglietto-Vargas D, Moreno-Gonzalez I, Sanchez-Varo R, Jimenez S, Trujillo-Estrada L, Sanchez-Mejias E, Torres M, Romero-Acebal M, Ruano D, Vizuete M, Vitorica J, Gutierrez A. 2010. Calretinin interneurons are early targets of extracellular amyloid-beta pathology in PS1/AbetaPP Alzheimer mice hippocampus. J Alzheimers Dis 21:119-132.
5. Beal MF, Mazurek MF, Svendsen CN, Bird ED, Martin JB. 1986. Widespread reduction of somatostatin-like immunoreactivity in the cerebral cortex in Alzheimer's disease. Ann Neurol 20:489-495.
6. Bhattacharyya R, Kovacs DM. 2010. ACAT inhibition and amyloid beta reduction. Biochim Biophys Acta 1801:960-965.
7. Braak H, Braak E. 1991. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 82:239-259.
8. Braak H, Rub U, Schultz C, Del Tredici K. 2006. Vulnerability of cortical neurons to Alzheimer's and Parkinson's diseases. J Alzheimers Dis 9:35-44.
9. Brady DR, Mufson EJ. 1997. Parvalbumin-immunoreactive neurons in the hippocampal formation of Alzheimer's diseased brain. Neuroscience 80:1113-1125.
10. Brunjes PC, Illig KR, Meyer EA. 2005. A field guide to the anterior olfactory nucleus (cortex). Brain Res Brain Res Rev 50:305-335.
11. Burgos-Ramos E, Hervas-Aguilar A, Aguado-Llera D, Puebla-Jimenez L, Hernandez-Pinto AM, Barrios V, Arilla-Ferreiro E. 2008. Somatostatin and Alzheimer's disease. Mol Cell Endocrinol 286:104-111.
12. Buxbaum JD, Thinakaran G, Koliatsos V, O'Callahan J, Slunt HH, Price DL, Sisodia SS. 1998. Alzheimer amyloid protein precursor in the rat hippocampus: transport and processing through the perforant path. J Neurosci 18:9629-9637.
13. Cai Y, Xue ZQ, Zhang XM, Li MB, Wang H, Luo XG, Cai H, Yan XX. 2012. An age-related axon terminal pathology around the first olfactory relay that involves amyloidogenic protein overexpression without plaque formation. Neuroscience 215:160-173.
14. Cao L, Rickenbacher GT, Rodriguez S, Moulia TW, Albers MW. 2012. The precision of axon targeting of mouse olfactory sensory neurons requires the BACE1 protease. Sci Rep 2:231.
15. Davies P. 1979. Neurotransmitter-related enzymes in senile dementia of the Alzheimer type. Brain Res 171:319-327.
16. Davies P, Katzman R, Terry RD. 1980. Reduced somatostatin-like immunoreactivity in cerebral cortex from cases of Alzheimer disease and Alzheimer senile dementa. Nature 288:279-280.
17. Djordjevic J, Jones-Gotman M, De Sousa K, Chertkow H. 2008. Olfaction in patients with mild cognitive impairment and Alzheimer's disease. Neurobiol Aging 29:693-706.
18. Doty RL. 2003. Odor perception in neurodegenerative diseases. New York: Marcel Dekker.
19. El-Amouri SS, Zhu H, Yu J, Marr R, Verma IM, Kindy MS. 2008. Neprilysin: an enzyme candidate to slow the progression of Alzheimer's disease. Am J Pathol 172:1342-1354.
20. Elder GA, De Gasperi R, Gama Sosa MA. 2006. Research update: neurogenesis in adult brain and neuropsychiatric disorders. Mt Sinai J Med 73:931-940.
21. Epelbaum J, Guillou JL, Gastambide F, Hoyer D, Duron E, Viollet C. 2009. Somatostatin, Alzheimer's disease and cognition: an old story coming of age? Progr Neurobiol 89:153-161.
22. Filali M, Lalonde R. 2009. Age-related cognitive decline and nesting behavior in an APPswe/PS1 bigenic model of Alzheimer's disease. Brain Res 1292:93-99.
23. Fonseca M, Soriano E. 1995. Calretinin-immunoreactive neurons in the normal human temporal cortex and in Alzheimer's disease. Brain Res 691:83-91.
24. Fotuhi M, Hachinski V, Whitehouse PJ. 2009. Changing perspectives regarding late-life dementia. Nat Rev Neurol 5:649-658.
25. Gahete MD, Rubio A, Duran-Prado M, Avila J, Luque RM, Castano JP. 2010. Expression of Somatostatin, cortistatin, and their receptors, as well as dopamine receptors, but not of neprilysin, are reduced in the temporal lobe of Alzheimer's disease patients. J Alzheimers Dis 20:465-475.
26. Guillery RW. 2002. On counting and counting errors. J Comp Neurol 447:1-7.
27. Hama E, Saido TC. 2005. Etiology of sporadic Alzheimer's disease: somatostatin, neprilysin, and amyloid beta peptide. Med Hypotheses 65:498-500.
28. Hawkes CH, Doty, R.L. 2009. The neurology of olfaction. Cambridge: Cambridge University Press.
29. Hernandez F, Avila J. 2008. Tau aggregates and tau pathology. J Alzheimers Dis 14:449-452.
30. Hof PR, Cox K, Young WG, Celio MR, Rogers J, Morrison JH. 1991. Parvalbumin-immunoreactive neurons in the neocortex are resistant to degeneration in Alzheimer's disease. J Neuropathol Exp Neurol 50:451-462.
31. Jankowsky JL, Fadale DJ, Anderson J, Xu GM, Gonzales V, Jenkins NA, Copeland NG, Lee MK, Younkin LH, Wagner SL, Younkin SG, Borchelt DR. 2004. Mutant presenilins specifically elevate the levels of the 42 residue beta-amyloid peptide in vivo: evidence for augmentation of a 42-specific gamma secretase. Hum Mol Genet 13:159-170.
32. Jankowsky JL, Slunt HH, Ratovitski T, Jenkins NA, Copeland NG, Borchelt DR. 2001. Co-expression of multiple transgenes in mouse CNS: a comparison of strategies. Biomol Eng 17:157-165.
33. Jellinger KA, Attems J. 2005. Alzheimer pathology in the olfactory bulb. Neuropathol Appl Neurobiol 31:203.
34. Leinwand SG, Chalasani SH. 2011. Olfactory networks: from sensation to perception. Curr Opin Genet Dev 21:806-811.
35. Lepousez G, Csaba Z, Bernard V, Loudes C, Videau C, Lacombe J, Epelbaum J, Viollet C. 2010a. Somatostatin interneurons delineate the inner part of the external plexiform layer in the mouse main olfactory bulb. J Comp Neurol 518:1976-1994.
36. Lepousez G, Mouret A, Loudes C, Epelbaum J, Viollet C. 2010b. Somatostatin contributes to in vivo gamma oscillation modulation and odor discrimination in the olfactory bulb. J Neurosci 30:870-875.
37. Liang B, Duan BY, Zhou XP, Gong JX, Luo ZG. 2010. Calpain activation promotes BACE1 expression, amyloid precursor protein processing, and amyloid plaque formation in a transgenic mouse model of Alzheimer disease. J Biol Chem 285:27737-27744.
38. Lu T, Pan Y, Kao SY, Li C, Kohane I, Chan J, Yankner BA. 2004. Gene regulation and DNA damage in the ageing human brain. Nature 429:883-891.
39. Mattson MP. 2007. Calcium and neurodegeneration. Aging Cell 6:337-350.
40. Mattson MP, Cheng B, Davis D, Bryant K, Lieberburg I, Rydel RE. 1992. beta-Amyloid peptides destabilize calcium homeostasis and render human cortical neurons vulnerable to excitotoxicity. J Neurosci 12:376-389.
41. Mikkonen M, Alafuzoff I, Tapiola T, Soininen H, Miettinen R. 1999. Subfield- and layer-specific changes in parvalbumin, calretinin and calbindin-D28K immunoreactivity in the entorhinal cortex in Alzheimer's disease. Neuroscience 92:515-532.
42. Miners JS, Baig S, Palmer J, Palmer LE, Kehoe PG, Love S. 2008. Abeta-degrading enzymes in Alzheimer's disease. Brain Pathol 18:240-252.
43. Nelson PT, Braak H, Markesbery WR. 2009. Neuropathology and cognitive impairment in Alzheimer disease: a complex but coherent relationship. J Neuropathol Exp Neurol 68:1-14.
44. Ohm TG, Braak H. 1987. Olfactory bulb changes in Alzheimer's disease. Acta Neuropathol 73:365-369.
45. Oliva AA, Jr., Jiang M, Lam T, Smith KL, Swann JW. 2000. Novel hippocampal interneuronal subtypes identified using transgenic mice that express green fluorescent protein in GABAergic interneurons. J Neurosci 20:3354-3368.
46. Parrish-Aungst S, Shipley MT, Erdelyi F, Szabo G, Puche AC. 2007. Quantitative analysis of neuronal diversity in the mouse olfactory bulb. J Comp Neurol 501:825-836.
47. Peers C, Dallas ML, Boycott HE, Scragg JL, Pearson HA, Boyle JP. 2009. Hypoxia and neurodegeneration. Ann N Y Acad Sci 1177:169-177.
48. Perrin RJ, Fagan AM, Holtzman DM. 2009. Multimodal techniques for diagnosis and prognosis of Alzheimer's disease. Nature 461:916-922.
49. Perry EK, Tomlinson BE, Blessed G, Bergmann K, Gibson PH, Perry RH. 1978. Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia. Br Med J 2:1457-1459.
50. Philpot BD, Lim JH, Brunjes PC. 1997. Activity-dependent regulation of calcium-binding proteins in the developing rat olfactory bulb. J Comp Neurol 387:12-26.
51. Poo C, Isaacson JS. 2011. A major role for intracortical circuits in the strength and tuning of odor-evoked excitation in olfactory cortex. Neuron 72:41-48.
52. Popovic M, Caballero-Bleda M, Kadish I, Van Groen T. 2008. Subfield and layer-specific depletion in calbindin-D28K, calretinin and parvalbumin immunoreactivity in the dentate gyrus of amyloid precursor protein/presenilin 1 transgenic mice. Neuroscience 155:182-191.
53. Price JL, Davis PB, Morris JC, White DL. 1991. The distribution of tangles, plaques and related immunohistochemical markers in healthy aging and Alzheimer's disease. Neurobiol Aging 12:295-312.
54. Qiu WQ, Walsh DM, Ye Z, Vekrellis K, Zhang J, Podlisny MB, Rosner MR, Safavi A, Hersh LB, Selkoe DJ. 1998. Insulin-degrading enzyme regulates extracellular levels of amyloid beta-protein by degradation. J Biol Chem 273:32730-32738.
55. Ramos B, Baglietto-Vargas D, del Rio JC, Moreno-Gonzalez I, Santa-Maria C, Jimenez S, Caballero C, Lopez-Tellez JF, Khan ZU, Ruano D, Gutierrez A, Vitorica J. 2006. Early neuropathology of somatostatin/NPY GABAergic cells in the hippocampus of a PS1xAPP transgenic model of Alzheimer's disease. Neurobiol Aging 27:1658-1672.
56. Rao MV, Mohan PS, Peterhoff CM, Yang DS, Schmidt SD, Stavrides PH, Campbell J, Chen Y, Jiang Y, Paskevich PA, Cataldo AM, Haroutunian V, Nixon RA. 2008. Marked calpastatin (CAST) depletion in Alzheimer's disease accelerates cytoskeleton disruption and neurodegeneration: neuroprotection by CAST overexpression. J Neurosci 28:12241-12254.
57. Reinikainen KJ, Soininen H, Riekkinen PJ. 1990. Neurotransmitter changes in Alzheimer's disease: implications to diagnostics and therapy. J Neurosci Res 27:576-586.
58. Reyes A, Lujan R, Rozov A, Burnashev N, Somogyi P, Sakmann B. 1998. Target-cell-specific facilitation and depression in neocortical circuits. Nat Neurosci 1:279-285.
59. Saito T, Iwata N, Tsubuki S, Takaki Y, Takano J, Huang SM, Suemoto T, Higuchi M, Saido TC. 2005. Somatostatin regulates brain amyloid beta peptide Abeta42 through modulation of proteolytic degradation. Nat Med 11:434-439.
60. Saiz-Sanchez D, Ubeda-Banon I, de la Rosa-Prieto C, Argandona-Palacios L, Garcia-Munozguren S, Insausti R, Martinez-Marcos A. 2010. Somatostatin, tau, and beta-amyloid within the anterior olfactory nucleus in Alzheimer disease. Exp Neurol 223:347-350.
61. Saiz-Sanchez D, Ubeda-Banon I, de La Rosa-Prieto C, Martinez-Marcos A. 2012. Differential expression of interneuron populations and correlation with amyloid-β deposition in the olfactory cortex of an AβPP/PS1 transgenic mouse model of Alzheimer's disease. J Alzheimers Dis 31:113-129.
62. Selkoe DJ. 2001. Alzheimer's disease: genes, proteins, and therapy. Physiol Rev 81:741-766.
63. Selkoe DJ. 2008. Biochemistry and molecular biology of amyloid beta-protein and the mechanism of Alzheimer's disease. Handb Clin Neurol 89:245-260.
64. Sheng JG, Price DL, Koliatsos VE. 2002. Disruption of corticocortical connections ameliorates amyloid burden in terminal fields in a transgenic model of Abeta amyloidosis. J Neurosci 22:9794-9799.
65. Solodkin A, Veldhuizen SD, Van Hoesen GW. 1996. Contingent vulnerability of entorhinal parvalbumin-containing neurons in Alzheimer's disease. J Neurosci 16:3311-3321.
66. Suzuki N, Bekkers JM. 2010. Inhibitory neurons in the anterior piriform cortex of the mouse: classification using molecular markers. J Comp Neurol 518:1670-1687.
67. Takahashi H, Brasnjevic I, Rutten BP, Van Der Kolk N, Perl DP, Bouras C, Steinbusch HW, Schmitz C, Hof PR, Dickstein DL. 2010. Hippocampal interneuron loss in an APP/PS1 double mutant mouse and in Alzheimer's disease. Brain Struct Funct 214:145-160.
68. Tamminga CA, Foster NL, Fedio P, Bird ED, Chase TN. 1987. Alzheimer's disease: low cerebral somatostatin levels correlate with impaired cognitive function and cortical metabolism. Neurology 37:161-165.
69. Tsuboi Y, Wszolek ZK, Graff-Radford NR, Cookson N, Dickson DW. 2003. Tau pathology in the olfactory bulb correlates with Braak stage, Lewy body pathology and apolipoprotein epsilon4. Neuropathol Appl Neurobiol 29:503-510.
70. van de Nes JA, Sandmann-Keil D, Braak H. 2002. Interstitial cells subjacent to the entorhinal region expressing somatostatin-28 immunoreactivity are susceptible to development of Alzheimer's disease-related cytoskeletal changes. Acta Neuropathol 104:351-356.
71. van Groen T, Kiliaan AJ, Kadish I. 2006. Deposition of mouse amyloid beta in human APP/PS1 double and single AD model transgenic mice. Neurobiol Dis 23:653-662.
72. Wang J, Tanila H, Puolivali J, Kadish I, van Groen T. 2003. Gender differences in the amount and deposition of amyloidbeta in APPswe and PS1 double transgenic mice. Neurobiol Dis 14:318-327.
73. Wang S, Wang R, Chen L, Bennett DA, Dickson DW, Wang DS. 2010. Expression and functional profiling of neprilysin, insulin-degrading enzyme, and endothelin-converting enzyme in prospectively studied elderly and Alzheimer's brain. J Neurochem 115:47-57.
74. Wesson DW, Levy E, Nixon RA, Wilson DA. 2010. Olfactory dysfunction correlates with amyloid-beta burden in an Alzheimer's disease mouse model. J Neurosci 30:505-514.
75. Wolansky T, Pagliardini S, Greer JJ, Dickson CT. 2007. Immunohistochemical characterization of substance P receptor (NK(1)R)-expressing interneurons in the entorhinal cortex. J Comp Neurol 502:427-441.
76. Young JW, Sharkey J, Finlayson K. 2009. Progressive impairment in olfactory working memory in a mouse model of mild cognitive impairment. Neurobiol Aging 30:1430-1443.